Key result
Four weeks of Montmorency cherry supplementation enhanced recovery of flow-mediated dilation after ischemia-reperfusion injury compared with placebo (ΔFMD -0.6% vs -25.4%; P=0.038).
Why the study?
Although flavonoid supplementation improves brachial artery flow-mediated dilation, whether flavonoids protect against vascular dysfunction induced by ischemia-reperfusion injury and associated respiratory burst was unknown.
Does Montmorency cherry supplementation improve flow-mediated dilation after ischemia-reperfusion injury in overweight, middle-aged men?
RCT (n=12)
Double-blind
randomized
Does Montmorency cherry supplementation improve flow-mediated dilation after ischemia-reperfusion injury in overweight, middle-aged men?
Absolute Event Rate: -0.6% vs -25.4%
p-value: p=0.038
Four weeks of Montmorency cherry supplementation enhances the recovery of endothelium-dependent vasodilation after transient ischemia-reperfusion injury in overweight, hypertensive middle-aged men.
Supports endothelial recovery after ischemia-reperfusion in overweight middle-aged men; extends polyphenol supplementation evidence to human vascular injury models.
Flavonoid supplementation improves brachial artery flow-mediated dilation (FMD), but it is not known whether flavonoids protect against vascular dysfunction induced by ischemia-reperfusion (IR) injury and associated respiratory burst. In a randomized, double-blind, placebo-controlled, crossover study, we investigated whether 4 wk supplementation with freeze-dried Montmorency cherry (MC) attenuated suppression of FMD after IR induced by prolonged forearm occlusion. Twelve physically inactive overweight, middle-aged men (52.8 ± 5.8 yr, BMI: 28.1 ± 5.3 kg/m2) consumed MC (235 mg/day anthocyanins) or placebo capsules for 4 wk, with supplementation blocks separated by 4 wk washout. Before and after each supplementation block, FMD responses and plasma nitrate and nitrite ([[Formula: see text]]) concentrations were measured at baseline and 15, 30, and 45 min after prolonged (20 min) forearm occlusion. FMD response was significantly depressed by the prolonged occlusion ( P < 0.001). After a 45-min reperfusion, FMD was restored to baseline levels after MC (ΔFMD presupplementation: −30.5 ± 8.4%, postsupplementation: −0.6 ± 9.5%) but not placebo supplementation (ΔFMD presupplementation: −11.6 ± 10.6, postsupplementation: −25.4 ± 4.0%; condition × supplement interaction: P = 0.038). Plasma [[Formula: see text]] decreased after prolonged occlusion but recovered faster after MC compared with placebo (Δ45 min to baseline; MC: presupplementation: −15.3 ± 9.6, postsupplementation: −6.2 ± 8.1; Placebo: presupplementation: −16.3 ± 5.9, postsupplementation: −27.7 ± 11.1 nmol/l; condition × supplement × time interaction: P = 0.033). Plasma peroxiredoxin concentration ([Prx2]) was significantly higher after MC (presupplementation: 22.8 ± 1.4, postsupplementation: 28.0 ± 2.4 ng/ml, P = 0.029) but not after placebo supplementation (presupplementation: 22.1 ± 2.2, postsupplementation: 23.7 ± 1.5 ng/ml). In conclusion, 4 wk MC supplementation enhanced recovery of endothelium-dependent vasodilatation after IR, in parallel with faster recovery of plasma [[Formula: see text]], suggesting NO dependency. These protective effects seem to be related to increased plasma [Prx2], presumably conferring protection against the respiratory burst during reperfusion. NEW & NOTEWORTHY This is the first study to demonstrate that 4 wk of Montmorency cherry powder supplementation exerted protective effects on endothelium-dependent vasodilation after transient ischemia-reperfusion injury in overweight, physically inactive, nonmedicated, hypertensive middle-aged men. These effects seem to be due to increased nitric oxide availability, as evidenced by higher plasma nitrite concentration and peak arterial diameter during the flow-mediated dilation measurement. This may be a consequence of increased concentration of peroxiredoxin and other antioxidant systems and, hence, reduced reactive oxygen species exposure.
No takes yet. Share an insight, caveat, or question.
Bakkar et al. (2018) conducted an RCT in overweight, physically inactive, nonmedicated, hypertensive middle-aged men (n=12). Montmorency cherry (MC) vs. placebo was evaluated on change in flow-mediated dilation (ΔFMD) after ischemia-reperfusion injury (p=0.038). Four weeks of Montmorency cherry supplementation enhanced recovery of flow-mediated dilation after ischemia-reperfusion injury compared with placebo (ΔFMD -0.6% vs -25.4%; P=0.038).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: